“And as these dynamics continue to play out and we continue to expand our innovation lead, we expect our CST business to deliver sustained above market growth.”

In context

“out of the spine business. We're causing this disruption. We're causing this disruption with our arsenal of differentiated enabling technology, including AI-driven preop planning software, imaging, robotics, navigation, and powered surgical instruments. And we recently expanded into pre- and post-op imaging through our partnership with Siemens Healthineers. Look, surgeons have to make a choice and they're standardizing with the company that can offer them this full complement of innovative technologies. And those competitors that can't or can only offer certain pieces, well, we're seeing them either struggle or just exit the market altogether. Our differentiated best-in-class AiBLE ecosystem is attracting the best spine surgeons, as well as the best reps and distributors from competitors. And as these dynamics continue to play out and we continue to expand our innovation lead, we expect our CST business to deliver sustained above market growth. Next, neuromodulation grew 13% well above the market. And just like in spine, our game-changing innovation and strong commercial execution is disrupting the competitive dynamics. The closed-loop sensing technology that we've developed for both pain stem and brain modulation has been a big engineering feat. We now have therapies that can be personalized at scale, which is better for patients and can lessen the load on the healthcare system. And it raises the bar on what it takes to compete, which is evident in our Neuromod growth. In Pain Stim we grew 12%, including 17% in the U.S., on the strength of our Inceptiv closed loop spinal cord stimulator. On top of being the smallest and thinnest SCS device, Inceptiv instantly adjusts based on neural responses to keep the therapy at an optimal d”